HAYWARD, Calif., Feb. 8 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the FDA on a SPA for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
In the Feb. 7, 2010, online edition of Nature Medicine, scientists described an anabolic approach to increasing bone mass: In rodents, they were able to increase osteoblast activity and, ultimately, bone mass and function, by inhibiting gut serotonin. Bone formation depends on two complementary processes mediated by two different cells. All in all, osteoporosis adds up to a growing health concern.
WASHINGTON -- Federal regulators have granted Anglo-Swedish drugmaker AstraZeneca approval to market its cholesterol pill Crestor as a preventive measure against heart attack and stroke in patients with healthy cholesterol levels.
JERUSALEM, ISRAEL, LUND, SWEDEN, February 8, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS).
SciClone Pharmaceuticals, Inc. and its partner Sigma-Tau S.p.A., announced additional topline results in a clinical study evaluating the potential of ZADAXIN to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria from Novartis.
Addex Pharmaceuticals, the allosteric modulation company, announced today that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. In the first model, ADX71943 reversed complete Freund adjuvant (CFA)- induced reductions in withdrawal thresholds in a dose-related manner, with a minimum statistically significant effective oral dose of 10 mg/kg.
